# Glutamine Supplementation and Exercise: A Narrative Review of Biochemical Mechanisms and Timing Strategies

**Authors:** Branka Djordjevic, Vladana Stojiljkovic, Aleksandra Velickov, Jana Kocic, Jelena Milenkovic, Andrej Veljkovic, Jelena Basic, Tatjana Cvetkovic

PMC · DOI: 10.3390/medicina62020329 · Medicina · 2026-02-06

## TL;DR

This review explores how glutamine supplementation may help with exercise recovery by supporting immune function, reducing stress, and improving muscle and intestinal health.

## Contribution

The paper synthesizes biochemical mechanisms and evaluates timing strategies for glutamine supplementation in exercise recovery.

## Key findings

- Glutamine may support muscle recovery and reduce oxidative stress after exercise.
- Post-exercise supplementation shows potential benefits for intestinal and muscle health.
- Clinical results are inconsistent, likely due to differences in study design and endpoints.

## Abstract

Intense physical activity imposes substantial oxidative, metabolic, and immunological stress on the human body. It is often accompanied by reductions in plasma glutamine levels, making this amino acid conditionally essential. Glutamine plays a vital role in energy production, nitrogen transport, acid–base balance, antioxidant defense, and immune function. It is required in the biosynthesis of neurotransmitters, nucleotides, nicotinamide-derived coenzymes, glutathione, and hexosamines, making it a candidate for supporting exercise recovery. In addition, glutamine may support key mechanisms involved in muscle adaptation and recovery during exercise-induced stress by contributing to redox balance, energy sensing, anabolic signaling, intestinal barrier integrity, and immune function. This narrative review aims to synthesize biochemical mechanisms underlying glutamine effects relevant to exercise and evaluate preclinical and clinical findings on supplementation outcomes, with emphasis on timing strategies. Preclinical findings demonstrate that glutamine can modulate protein synthesis, reduce oxidative stress, improve intestinal integrity, and attenuate immune and inflammatory disturbances. Limited preclinical data suggest that post-exercise supplementation may better resolve muscle and organ damage. Clinical trials, however, report heterogeneous outcomes: several studies show improvements in markers of intestinal permeability and intestinal epithelial damage, oxidative stress, muscle damage, and inflammation, whereas others report minimal or no effect, including limited influence on performance outcomes. Variability in timing protocols, participant characteristics, and measured endpoints contributes to inconsistent findings. Overall, glutamine demonstrates several biologically plausible mechanisms that could support recovery and overall health in active individuals, athletes, and specific clinical populations. However, current evidence remains insufficient to determine clear supplementation benefits or define an optimal timing strategy. Future research using standardized protocols and integrated biochemical and functional endpoints is needed to clarify timing effects. Until such evidence emerges, recommendations should remain individualized, considering athlete-specific needs.

## Linked entities

- **Chemicals:** glutamine (PubChem CID 738)

## Full-text entities

- **Genes:** GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, SLC15A1 (solute carrier family 15 member 1) [NCBI Gene 6564] {aka HPECT1, HPEPT1, PEPT1}, GLUL (glutamate-ammonia ligase) [NCBI Gene 2752] {aka DEE116, GLNS, GS, PIG43, PIG59}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) [NCBI Gene 54704] {aka PDH, PDP, PDPC, PDPC 1, PPM2A, PPM2C}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, SLC1A5 (solute carrier family 1 member 5) [NCBI Gene 6510] {aka AAAT, ASCT2, ATBO, M7V1, M7VS1, R16}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, NADSYN1 (NAD synthetase 1) [NCBI Gene 55191] {aka VCRL3}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, PON1 (paraoxonase 1) [NCBI Gene 5444] {aka ESA, MVCD5, PON}, GFPT1 (glutamine--fructose-6-phosphate transaminase 1) [NCBI Gene 2673] {aka CMS12, CMSTA1, GFA, GFAT, GFAT 1, GFAT1}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ME2 (malic enzyme 2) [NCBI Gene 4200] {aka ODS1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CLDN2 (claudin 2) [NCBI Gene 9075] {aka OAZON, claudin-2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCL21 (C-C motif chemokine ligand 21) [NCBI Gene 6366] {aka 6Ckine, CKb9, ECL, SCYA21, SLC, TCA4}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC38A2 (solute carrier family 38 member 2) [NCBI Gene 54407] {aka ATA2, PRO1068, SAT2, SNAT2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, HSP90B2P (heat shock protein 90 beta family member 2, pseudogene) [NCBI Gene 7190] {aka GRP94P1, GRP94b, HSP, HSPCP2, TRA1P1, TRAP1}, H6PD (hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase) [NCBI Gene 9563] {aka CORTRD1, G6PDH, GDH, H6PDH}, FABP2 (fatty acid binding protein 2) [NCBI Gene 2169] {aka FABPI, I-FABP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PRX (periaxin) [NCBI Gene 57716] {aka CMT4F}, SLC38A1 (solute carrier family 38 member 1) [NCBI Gene 81539] {aka ATA1, NAT2, SAT1, SNAT1}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, DECR1 (2,4-dienoyl-CoA reductase 1) [NCBI Gene 1666] {aka DECR, NADPH, SDR18C1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, SLC6A19 (solute carrier family 6 member 19) [NCBI Gene 340024] {aka B0AT1, HND}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, HSF1 (heat shock transcription factor 1) [NCBI Gene 3297] {aka HSTF1}, HEBP1 (heme binding protein 1) [NCBI Gene 50865] {aka HBP, HEBP}
- **Diseases:** intestinal injury (MESH:D007410), HIV/AIDS (MESH:D015658), ulcerative colitis (MESH:D003093), tissue injury (MESH:D017695), adiposity (MESH:D018205), cardiac and kidney injury (MESH:D007674), muscle and organ damage (MESH:D000092124), type 1 diabetes (MESH:D003922), Muscle soreness (MESH:D063806), muscular damage (MESH:D009135), gastrointestinal discomfort (MESH:D005767), immune (MESH:D007154), infection (MESH:D007239), hypoglycemia (MESH:D007003), CD (MESH:D003424), muscle hypertrophy (MESH:C536106), ischemia (MESH:D007511), hypoxia (MESH:D000860), overtraining syndrome (MESH:D000095027), obesity (MESH:D009765), nausea (MESH:D009325), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (MESH:D000163), fatigue (MESH:D005221), cancer (MESH:D009369), diabetes (MESH:D003920), critically ill (MESH:D016638), metabolic syndrome (MESH:D024821), gastrointestinal symptoms (MESH:D012817), muscle damage (MESH:D009133), inflammation (MESH:D007249), upper respiratory tract infection (MESH:D012141), injury (MESH:D014947), muscle (MESH:D019042), dyslipidemia (MESH:D050171), gastrointestinal pain (MESH:D010146)
- **Chemicals:** TBARS (MESH:D017392), tryptophan (MESH:D014364), DIP (MESH:C067227), Dopamine (MESH:D004298), NAD (MESH:D009243), Deamido-NAD+ (MESH:C018348), ROS (MESH:D017382), Hexosamine (MESH:D006595), glucose (MESH:D005947), 5-HT (MESH:D012701), NR (MESH:C018613), mannitol (MESH:D008353), Gln (MESH:D005973), citrate (MESH:D019343), GSH (MESH:D005978), ATP (MESH:D000255), AMP (MESH:D000249), purine (MESH:C030985), Cys (MESH:D003545), lipid (MESH:D008055), amino acid (MESH:D000596), Nitrite (MESH:D009573), urea (MESH:D014508), NADP+ (MESH:D009249), niacin (MESH:D009525), OAA (MESH:D062907), rhamnose (MESH:D012210), aspartate (MESH:D001224), carbohydrates (MESH:D002241), fatty acid (MESH:D005227), Malondialdehyde (MESH:D008315), arginine (MESH:D001120), CET (MESH:D002512), GSSG (MESH:D019803), NO (MESH:D009614), ornithine (MESH:D009952), UDP-N-acetylglucosamine (MESH:D014537), MD (MESH:D008573), 2-OG:2-oxoglutarate (-), hydrogen peroxide (MESH:D006861), disulfide (MESH:D004220), Na+ (MESH:D012964), cystine (MESH:D003553), neutral amino acids (MESH:D021542), 2-oxoglutarate (MESH:D007656), fructose-6-phosphate (MESH:C027618), NO-3 (MESH:C038619), Glu (MESH:D018698), citrulline (MESH:D002956), GABA (MESH:D005680), pyrimidine (MESH:C030986), Dipeptide (MESH:D004151), blood glucose (MESH:D001786), Gly (MESH:D005998), malate (MESH:C030298), asparagine (MESH:D001216), Cholesterol (MESH:D002784), Nitric Oxide (MESH:D009569), alanyl-glutamine (MESH:C054122), Nicotinamide (MESH:D009536)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** glutamine to glutamate

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942590/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942590/full.md

## References

89 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942590/full.md

---
Source: https://tomesphere.com/paper/PMC12942590